Drugs / SMART101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05768035 | Jun 2023 → Jul 2025 overdue | hematopoietic and lymphoid cell neoplasm | Smart Immune SAS | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04959903 | Mar 2022 → Aug 2025 overdue | hematopoietic and lymphoid cell neoplasm | Smart Immune SAS | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMART101 | “The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after...” NCT05768035 ↗1“The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell...” NCT04959903 ↗ |
| Known as | Human T Lymphoid Progenitor (HTLP) | “The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell...” NCT04959903 ↗ |
| Modality | Cell therapy | “Allogeneic T cell progenitors, cultured ex-vivo” NCT04959903 ↗ |